Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences: Director Stefan Loren to leave board; Nantahala designee Andrew Gu appointed

Neutral Impact 3 of 5 leadership Written later

Cellectar director Stefan Loren will not stand for reelection at the 2026 annual meeting, and the Board appointed Andrew Gu, an analyst at hedge fund Nantahala Capital Management, as a Class III director and Audit Committee member on May 18, 2026. The change follows a May 4, 2026 securities purchase agreement in which Nantahala secured a board designation right, and the filing says Dr. Loren's decision was not due to any disagreement with the Company.

Key points

  • Stefan D. Loren, Ph.D. notified the Board on May 17, 2026 that he will not seek reelection as a Class III director.
  • Andrew Gu was appointed to the Board as a Class III director and to the Audit Committee on May 18, 2026, as Nantahala's designee.
  • Dr. Loren will provide consulting services for one year, starting July 8, 2026, for $15,000 per quarter, plus a stock option grant of 15,000 shares at the end of the term.

The filing

CompanyCellectar Biosciences, Inc. (CLRB)
Form8-K, current report
Filed with the SECMay 18, 2026, 4:15 PM ET
Accession number0001104659-26-063202

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.